PTC Therapeutics, Inc. discovers and develops small molecule drugs by applying its integrated RNA biology and chemistry platforms. PTC's compounds modulate gene expression by selectively binding to either RNA targets or proteins that interact with RNA. This approach has progressed the Company's drug discovery programs rapidly from targets to lead optimization. PTC's pipeline includes programs in infectious diseases, oncology, inflammation and genetic disorders.
Array (  => Alissa Cadigan - RSM US  => Ashley Sarohkian - Capital One  => Badri Nittoor - eureQa  => Benjamin Novak - Morgan Lewis  => Bin Guan - Yorktel  => Blake Goodman - JLL  => Bret Morgan - CoWerking  => Chris DeMayo - Withum  => Christina Giglio - Robert Half  => David Powell - Mission50  => George Abraham - Rhodium Strategies  => Hitesh Ramani - Deloitte  => Jennifer Core - BDO  => Joshua Goldberg - Nathlaw  => Kelly Ford - Edison Partners  => Kevin Askew - TechXtend  => Kevin Richards - Princeton Identity  => Marc McCabe - Crystal & Company  => Matt DeJesus - ViaWest  => Michael Crafton - Alvarez & Marsal  => Michael Dietze - TierPoint  => Michelle Capezza - Epstein Becker & Green  => Mike Funk - Alliant Tech  => Mike Profit - WorkWave  => Parag Pruthi - Niksun  => Phil Kennard - Futurestay  => Phil Romero - Grant Thornton  => Ryan Sydorko - EY  => Scott Cowan - DLA Piper  => Tim Dluoik - KPMG  => Timur Pakay - FDU  => Vijay Ajuwalia - Edward Jones )